Control of osteoclast activity and bone loss by IKK subunits: New targets for therapy

Advances in Experimental Medicine and Biology

Volumn 602, Issue , 2007, Pages 125-134

  Ruocco, Maria Grazia ^a   Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ETANERCEPT; GLUCOCORTICOID; GOLD DERIVATIVE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SALAZOSULFAPYRIDINE; SALICYLATE SODIUM; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; I KAPPA B KINASE; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; BONE REMODELING; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MATURATION; CONFERENCE PAPER; ENZYME INHIBITION; HUMAN; INFLAMMATION; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; ARTICLE; DRUG ANTAGONISM; METABOLISM; MOUSE;

MUS;

ANIMALS; APOPTOSIS; ARTHRITIS, RHEUMATOID; BONE REMODELING; BONE RESORPTION; I-KAPPA B KINASE; MICE; NF-KAPPA B; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38449099230     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-72009-8_16     Document Type: Conference Paper

References (82)

1. Abu-Amer, Y., J. Erdmann, et al. 2000. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275(35): 27307-27310.
2. Barnes, P.J., and M. Karin. 1997. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336(15): 1066-1071.
3. Bathon, J.M., R.W. Martin, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22): 1586-1593.
4. Bolon, B., G. Campagnuolo, et al. 2002. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci 59(9): 1569-1576.
5. Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25(6): 280-288.
6. Boyle, W.J., W.S. Simonet, et al. 2003. Osteoclast differentiation and activation. Nature 423(6937): 337-342.
7. Breedveld, F.C., P. Emery, et al. 2004. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63(2): 149-155.
8. Campagnuolo, G., B. Bolon, et al. 2002. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 46(7): 1926-1936.
9. Campbell, I.K., S. Gerondakis, et al. 2000. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 105(12): 1799-1806.
10. Campbell, I.K., K. O'Donnell, et al. 2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 107(12): 1519-1527.
11. Chellaiah, M., C. Fitzgerald, et al. 1998. c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase. J Biol Chem 273(19): 11908-11916.
12. Danning, C.L., G.G. Illei, et al. 2000. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43(6): 1244-1256.
13. den Broeder, A., L. van de Putte, et al. 2002. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29(11): 2288-2298.
14. den Broeder, A.A., L.A. Joosten, et al. 2002. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61(4): 311-318.
15. Dougall, W.C., M. Glaccum, et al. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev 13(18): 2412-2424.
16. Duong, L.T., P.T. Lakkakorpi, et al. 1998. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J Clin Invest 102(5): 881-892.
17. Elliott, M.J., R.N. Maini, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930): 1105-1110.
18. Epinat, J.C., and T. D. Gilmore. 1999. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 18(49): 6896-6909.
19. Foxwell, B., K. Browne, et al. 1998. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A 95(14): 8211-8215.
20. Franzoso, G., L. Carlson, et al. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11(24): 3482-3496.
21. Genovese, M.C., J.M. Bathon, et al. 2002. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46(6): 1443-1450.
22. Ghosh, S., M.J. May, et al. 1998. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260.
23. Gravallese, E.M., 2002. Bone destruction in arthritis. Ann Rheum Dis 61(Suppl 2): ii84-ii86.
24. Hsu, H., H.B. Shu, et al. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84(2): 299-308.
25. Hu, Y., V. Baud, et al. 1999. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284(5412): 316-320.
26. Hu, Y., V. Baud, et al. 2001. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 410(6829): 710-714.
27. Iotsova, V., J. Caamano, et al. 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3(11): 1285-1289.
28. Ji, H., A. Pettit, et al. 2002. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196(1): 77-85.
29. Jimi, E., K. Aoki, et al. 2004. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10(6): 617-624.
30. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663.
31. Karin, M., and A. Lin. 2002. NF-kappaB at the crossroads of life and death. Nat Immunol 3(3): 221-227.
32. Karsenty, G., and E.F. Wagner. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2(4): 389-406.
33. Kobayashi, K., N. Takahashi, et al. 2000. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191(2): 275-286.
34. Kong, Y.Y., U. Feige, et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759): 304-309.
35. Kong, Y.Y., H. Yoshida, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397(6717): 315-323.
36. Kremer, J.M., M.E. Weinblatt, et al. 2003. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 48(6): 1493-1499.
37. Lacey, D.L., E. Timms, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2): 165-176.
38. Lam, J., S. Takeshita, et al. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106(12): 1481-1488.
39. Lawrence, T., D.A. Willoughby, et al. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2(10): 787-795.
40. Lee, S.E., K.M. Woo, et al. 2002. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30(1): 71-77.
41. Leisen, J.C., H. Duncan, et al. 1988. The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. J Rheumatol 15(1): 17-22.
42. Li, Q., D. Van Antwerp, et al. 1999. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284(5412): 321-325.
43. Li, Z.W., W. Chu, et al. 1999. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189(11): 1839-1845.
44. Lipsky, P.E., D.M. van der Heijde, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22): 1594-1602.
45. Liu, Z.G., H. Hsu, et al. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87(3): 565-576.
46. MacNaul, K.L., N.I. Hutchinson, et al. 1990. Analysis of IL-1 and TNF-alpha gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization. J Immunol 145(12): 4154-4166.
47. Maeda, S., L. Chang, et al. 2003. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 19(5): 725-737.
48. Maini, R., E.W. St. Clair, et al. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194): 1932-1939.
49. Maini, R.N., F.C. Breedveld, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9): 1552-1563.
50. Mercurio, F., H. Zhu, et al. 1997. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 2785339: 860-866.
51. Miagkov, A.V., D.V. Kovalenko, et al. 1998. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 95(23): 13859-13864.
52. Moreland, L.W., S.W. Baumgartner, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337(3): 141-7.
53. Moreland, L.W., M.H. Schiff, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6): 478-486.
54. Mostov, K., and Z. Werb (1997). Journey across the osteoclast. Science 276(5310): 219-220.
55. Nakashima, T., T. Wada, et al. 2003. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 15(3): 280-287.
56. Novack, D.V., L. Yin, et al. 2003. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198(5): 771-781.
57. Pettit, A.R., H. Ji, et al. 2001. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159(5): 1689-1699.
58. Reddi, A.H. 1997. Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state. Cell 89(2): 159-161.
59. Redlich, K., S. Hayer, et al. 2002. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110(10): 1419-1427.
60. Romas, E., N.A. Sims, et al. 2002. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161(4): 1419-1427.
61. Roodman, G.D. 1999. Cell biology of the osteoclast. Exp Hematol 27(8): 1229-1241.
62. Rothwarf, D.M., and M. Karin. 1999. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999(5): RE1.
63. Ruocco, M.G., S. Maeda, et al. 2005. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201(10): 1677-1687.
64. Sato, T., C. Selleri, et al. 1997. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol 97(2): 356-365.
65. Schett, G., K. Redlich, et al. 2003. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48(7): 2042-2051.
66. Seetharaman, R., A.L. Mora, et al. 1999. Essential role of T cell NF-kappa B activation in collagen-induced arthritis. J Immunol 163(3): 1577-1583.
67. Senftleben, U., Y. Cao, et al. 2001. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293(5534): 1495-1499.
68. Senftleben, U., Z.W. Li, et al. 2001. IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 14(3): 217-230.
69. Shealy, D.J., P.H. Wooley, et al. 2002. Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res 4(5): R7.
70. Shinkura, R., K. Kitada, et al. 1999. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet 22(1): 74-77.
71. Simonet, W.S., D.L. Lacey, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2): 309-319.
72. Soriano, P., C. Montgomery, et al. 1991. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64(4): 693-702.
73. Suzuki, Y., F. Nishikaku, et al. 1998. Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol 25(6): 1154-1160.
74. Tak, P.P., and G.S. Firestein. 2001. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107(1): 7-11.
75. Tanaka, S., M. Amling, et al. 1996. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383(6600): 528-531.
76. Weinblatt, M.E., E.C. Keystone, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1): 35-45.
77. Weinblatt, M.E., J.M. Kremer, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4): 253-259.
78. Wong, B.R., D. Besser, et al. 1999. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4(6): 1041-1049.
79. Zandi, E., D.M. Rothwarf, et al. 1997. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91(2): 243-252.
80. Zhang, Y.H., A. Heulsmann, et al. 2001. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276(1): 563-568.
81. Zou, W., I. Hakim, et al. 2001. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 83(1): 70-83.
82. Zwerina, J., S. Hayer, et al. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50(1): 277-290.